Janus Henderson Group PLC Cuts Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)

Janus Henderson Group PLC lowered its holdings in Immunic, Inc. (NASDAQ:IMUX) by 47.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,689,082 shares of the company’s stock after selling 2,410,196 shares during the quarter. Janus Henderson Group PLC owned approximately 2.99% of Immunic worth $2,689,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. 683 Capital Management LLC raised its stake in Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after buying an additional 15,349 shares in the last quarter. Bridgeway Capital Management LLC increased its holdings in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after acquiring an additional 22,200 shares during the period. Focus Partners Wealth increased its holdings in shares of Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after acquiring an additional 23,610 shares during the period. Invesco Ltd. bought a new position in shares of Immunic in the 4th quarter worth $37,000. Finally, HB Wealth Management LLC purchased a new stake in shares of Immunic during the 4th quarter worth $81,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on IMUX. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. B. Riley reissued a “buy” rating and set a $6.00 target price on shares of Immunic in a research report on Wednesday, April 16th. William Blair restated an “outperform” rating on shares of Immunic in a research note on Friday, May 16th. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Immunic in a report on Wednesday, April 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Immunic in a report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $13.20.

Immunic Trading Up 1.3%

NASDAQ IMUX opened at $0.97 on Wednesday. Immunic, Inc. has a 12-month low of $0.83 and a 12-month high of $2.11. The company has a fifty day simple moving average of $1.05 and a two-hundred day simple moving average of $1.08. The stock has a market cap of $93.29 million, a P/E ratio of -0.79 and a beta of 1.73.

Immunic (NASDAQ:IMUX) last released its earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). As a group, sell-side analysts forecast that Immunic, Inc. will post -0.94 earnings per share for the current year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.